TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11561228

Group type: EXPERIMENTAL
Intervention: 80 mg valsartan
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 160 mg valsartan
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 9990360

Group type: EXPERIMENTAL
Intervention: Calcipotriol treatment for 4 and 7 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcipotriol treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 0
Study: 8090631

Group type: EXPERIMENTAL
Intervention: Intravenous treatment of hyperthyroidism (0.81 GBq)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intravenous treatment of differentiated thyroid cancer (1.85 GBq)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oral treatment of hyperthyroidism (0.81 GBq)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oral treatment of differentiated thyroid cancer (1.85 GBq)
Number of subjects: 40
Study: 3056057

Group type: EXPERIMENTAL
Intervention: Cyclosporine and prednisone
Number of subjects: 246

Group type: COMPARATOR
Intervention: Azathioprine, prednisone, and antilymphocyte globulin
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Severely hyperuricemic patients (all on cyclosporine and prednisone)
Number of subjects: 246
Study: 30744610

Group type: EXPERIMENTAL
Intervention: Blended low-intensity psychological intervention using information and communication technologies (ICTs) combined with improved usual care.
Number of subjects: 300

Group type: COMPARATOR
Intervention: Improved treatment as usual (control group).
Number of subjects: 300
Study: 29582888

Group type: EXPERIMENTAL
Intervention: 25OHD (10 μg/day)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study: 26647154

Group type: EXPERIMENTAL
Intervention: School meals
Number of subjects: 530

Group type: COMPARATOR
Intervention: Lunch from home
Number of subjects: 530
Study: 25249652

Group type: EXPERIMENTAL
Intervention: PHEN/TPM ER 15 mg/92 mg (15/92)
Number of subjects: 518

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 518
Study: 22830622

Group type: EXPERIMENTAL
Intervention: Tai Chi exercise + Auricular acupressure (n=14)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Tai Chi exercise (n=7)
Number of subjects: 21
Study: 18712575

Group type: EXPERIMENTAL
Intervention: Laparotomic gastric bypass with omentectomy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Laparotomic gastric bypass without omentectomy
Number of subjects: 70
Study: 17985826

Group type: EXPERIMENTAL
Intervention: High-linoleate sunflower seed oil
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Aquaphor Original Emollient Ointment
Number of subjects: 405

Group type: COMPARATOR
Intervention: Usual care (comparison group)
Number of subjects: 405
Study: 16131946

Group type: EXPERIMENTAL
Intervention: Combined treatment (pharmacotherapy and psychotherapy)
Number of subjects: 0
Study: 12035990

Group type: EXPERIMENTAL
Intervention: Focus Toric (Ciba Vision)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: FreshLook Toric (Wesley lessen)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Acuvue Toric (Vistakon)
Number of subjects: 14
Study: 10101736

Group type: EXPERIMENTAL
Intervention: Dexamethasone 2 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7594099

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (specific agent not mentioned); administered during menstruation.
Number of subjects: 12
Study: 2178930

Group type: EXPERIMENTAL
Intervention: Oral isosorbide 5-mononitrate (ISMN)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Oral isosorbide 5-mononitrate (ISMN) with heart failure
Number of subjects: 360

Group type: COMPARATOR
Intervention: Control (placebo) with heart failure
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Oral isosorbide 5-mononitrate (ISMN) without heart failure
Number of subjects: 360

Group type: COMPARATOR
Intervention: Control (placebo) without heart failure
Number of subjects: 360
Study: 378053

Group type: EXPERIMENTAL
Intervention: Intranasal corticosteroid aerosol (beclomethasone dipropionate)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (placebo or no treatment)
Number of subjects: 34
Study: 6925576

Group type: EXPERIMENTAL
Intervention: Cimetidine (oral)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 4
Study: 29081307

Group type: EXPERIMENTAL
Intervention: vortioxetine 5 mg for 8 weeks
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: vortioxetine 5 or 10 mg for 20 weeks, then randomized to vortioxetine or placebo for at least 24 weeks
Number of subjects: 301

Group type: COMPARATOR
Intervention: placebo for 8 weeks
Number of subjects: 301

Group type: COMPARATOR
Intervention: placebo after 20 weeks of vortioxetine treatment
Number of subjects: 301
Study: 29461913

Group type: EXPERIMENTAL
Intervention: TetIV
Number of subjects: 350

Group type: COMPARATOR
Intervention: TriIV
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: TetIV and TriIV
Number of subjects: 350
Study: 27993169

Group type: EXPERIMENTAL
Intervention: Individualized exercise prescription (ventilatory thresholds)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standardized exercise prescription (HRR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individualized and standardized exercise prescriptions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified exercise prescription for non-responders
Number of subjects: 0
Study: 25366684

Group type: EXPERIMENTAL
Intervention: Standard care plus two APN telephone counseling sessions (n = 238)
Number of subjects: 472

Group type: COMPARATOR
Intervention: Standard care (n = 234)
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: APN counseling
Number of subjects: 472
Study: 22487270

Group type: EXPERIMENTAL
Intervention: 3D locking titanium miniplates
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard miniplate fixation
Number of subjects: 10
Study: 19194342

Group type: EXPERIMENTAL
Intervention: St. John's wort extract (900 mg TID)
Number of subjects: 47
Study: 17485023

Group type: EXPERIMENTAL
Intervention: Telmisartan (n = 30)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Valsartan (Control group, n = 21)
Number of subjects: 53
Study: 15240578

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 363
Study: 12012144

Group type: EXPERIMENTAL
Intervention: Test product (60 mg) after high-fat American breakfast
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Test product (60 mg) under fasted conditions
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference product (60 mg) after high-fat American breakfast
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference product (60 mg) under fasted conditions
Number of subjects: 24
Study: 10523801

Group type: EXPERIMENTAL
Intervention: 800 mg/d oral clodronate
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 1600 mg/d oral clodronate
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no clodronate)
Number of subjects: 50
Study: 7669316

Group type: EXPERIMENTAL
Intervention: Sevoflurane (start: 1%, maximum: 7%)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Halothane (start: 0.5%, maximum: 5%)
Number of subjects: 40
Study: 2140330

Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg twice daily for a maximum of 14 days
Number of subjects: 72

Group type: COMPARATOR
Intervention: Josamycin 1000 mg twice daily for a maximum of 14 days
Number of subjects: 72
Study: 7367177

Group type: EXPERIMENTAL
Intervention: Frontalis EMG feedback
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non‐contingent feedback
Number of subjects: 60

Group type: COMPARATOR
Intervention: Self-relaxation
Number of subjects: 60
Study: 30883164

Group type: EXPERIMENTAL
Intervention: Barrier Reduction Intervention (BRI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (no intervention)
Number of subjects: 0
Study: 27565129

Group type: EXPERIMENTAL
Intervention: Storage at 4 ± 2°C for up to 48 hr
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Storage at 23 ± 2°C for up to 48 hr
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Storage at 31 ± 2°C for up to 48 hr
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: All temperatures (4 ± 2°C, 23 ± 2°C, 31 ± 2°C) for up to 48 hr
Number of subjects: 102
Study: 26291953

Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication (LF)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Open Nissen fundoplication (OF)
Number of subjects: 87
Study: 23866988

Group type: EXPERIMENTAL
Intervention: Reinforced on-site integrated care (ROIC)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Standard on-site integrated care (SOIC)
Number of subjects: 125
Study: 21192153

Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (36 mg/d to 108 mg/d)
Number of subjects: 550
Study: 19038378

Group type: EXPERIMENTAL
Intervention: Writing prompts based on cognitive restructuring techniques
Number of subjects: 38

Group type: COMPARATOR
Intervention: Unstructured writing about a recent problematic social situation
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Greater purposeful engagement ability
Number of subjects: 38
Study: 17206296

Group type: EXPERIMENTAL
Intervention: Management at primary care level
Number of subjects: 201

Group type: COMPARATOR
Intervention: Advanced age
Number of subjects: 201

Group type: COMPARATOR
Intervention: Presence of diabetes
Number of subjects: 201
Study: 15082950

Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sham TENS
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 90
Study: 12423181

Group type: EXPERIMENTAL
Intervention: Complex method (sets of half squats before sets of jump squats)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Contrast method (alternation of sets of half squats and jump squats)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Traditional method (sets of power exercises before sets of half squats)
Number of subjects: 11
Study: 12669743

Group type: EXPERIMENTAL
Intervention: Alendronate therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alendronate
Number of subjects: 0
Study: 7755380

Group type: EXPERIMENTAL
Intervention: Endocrine therapy with adreno-oophorectomy
Number of subjects: 371

Group type: COMPARATOR
Intervention: Chemo-endocrine therapy with FAC
Number of subjects: 371
Study: 1980201

Group type: EXPERIMENTAL
Intervention: 0.4 mg suriclone
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: lorazepam (2 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 0.2 mg suriclone
Number of subjects: 16
Study: 6968611

Group type: EXPERIMENTAL
Intervention: Bulk laxative and a large anal dilator
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bulk laxative only
Number of subjects: 40
Study: 31797035

Group type: EXPERIMENTAL
Intervention: Cold-water immersion (CWI) - 5 minutes at 6 °C, excluding the head (n=9)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Passive recovery (CON) (n=9)
Number of subjects: 18
Study: 30295731

Group type: EXPERIMENTAL
Intervention: Mifepristone pre-treatment for 2 months prior to LNG-IUS insertion
Number of subjects: 58

Group type: COMPARATOR
Intervention: Comparator group (no mifepristone pre-treatment)
Number of subjects: 58
Study: 27543440

Group type: EXPERIMENTAL
Intervention: Early coronary blood flow (CBF) to left ventricular (LV) systolic function ratios (stunning index)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Early coronary blood flow (CBF) to left ventricular wall motion score index (LVMSI) ratios
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Early coronary blood flow (CBF) to left anterior descending wall motion score index (LADWMSI) ratios
Number of subjects: 24
Study: 25295804

Group type: EXPERIMENTAL
Intervention: C1 inhibitor (C1 INH‐nf; human) 1000 U intravenous injections every 3-4 days for 12 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 21477164

Group type: EXPERIMENTAL
Intervention: Whole-body cryotherapy (-110 ± 3 °C)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (15 ± 3 °C)
Number of subjects: 36
Study: 19593157

Group type: EXPERIMENTAL
Intervention: Six-Minute Walk Test
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (healthy age-matched and sex-matched individuals)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 18538705

Group type: EXPERIMENTAL
Intervention: Sterile water
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.05% CHG
Number of subjects: 20
Study: 16032934

Group type: EXPERIMENTAL
Intervention: HFA‐BDP 160 mcg twice daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: CFC‐FP 220 microg each morning and 110 microg each evening
Number of subjects: 30
Study: 12455197

Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine (LAC)
Number of subjects: 333

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 333
Study: 10653204

Group type: EXPERIMENTAL
Intervention: Clonazepam 1 mg and Sertraline 100 mg (CZ + SR)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Clonazepam 1 mg and Placebo (CZ + PL)
Number of subjects: 13
Study: 8559528

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE2) tablets (3 mg)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Oxytocin (continuous intravenous drip)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Atad Ripener Device
Number of subjects: 95
Study: 1814144

Group type: EXPERIMENTAL
Intervention: Short words consisting of fricative consonant/vowel combinations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Categorization task with words
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tone 'probes' presented randomly to either ear with speech sounds to one ear
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual input from articulatory movements of the speaker
Number of subjects: 0
Study: 6880563

Group type: EXPERIMENTAL
Intervention: Chlorpropamide (250 mg) administered once
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Repeated administrations of chlorpropamide (250 mg b.i.d. for 2 days)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Metergoline (antiserotonin agent) and bromocriptine (dopamine-agonist)
Number of subjects: 130
Study: 31627309

Group type: EXPERIMENTAL
Intervention: ELASTEN® (collagen supplement)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 29402908

Group type: EXPERIMENTAL
Intervention: Enhanced Reality (ER) analgesia, 5 times a week for 2 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Enhanced Reality (ER) analgesia, 5 times a week for 1 week
Number of subjects: 60
Study: 27448328

Group type: EXPERIMENTAL
Intervention: Retigabine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 25286167

Group type: EXPERIMENTAL
Intervention: Computer-aided telephone counselling for one year, supported by mailed newsletters
Number of subjects: 289

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 289
Study: 22192246

Group type: EXPERIMENTAL
Intervention: saxagliptin + metformin XR 1500 mg
Number of subjects: 282

Group type: COMPARATOR
Intervention: uptitrated metformin XR 2000 mg
Number of subjects: 282
Study: 20156668

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 20
Study: 17662012

Group type: EXPERIMENTAL
Intervention: Topiramate 100 mg/day
Number of subjects: 758

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 758
Study: 16055373

Group type: EXPERIMENTAL
Intervention: Difficult visual task (digits 1-4)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Easy visual task (letters X)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nociceptive CO2 laser stimuli
Number of subjects: 0
Study: 12325487

Group type: EXPERIMENTAL
Intervention: 3 capsules of 100 mg APD
Number of subjects: 8

Group type: COMPARATOR
Intervention: 2 tablets of 150 mg APD
Number of subjects: 8
Study: 10404554

Group type: EXPERIMENTAL
Intervention: Daily cigarette consumption scenarios with varying nicotine concentrations
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: High levels of cigarette consumption
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Adolescents compared to adults
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Overall perception of risk
Number of subjects: 155
Study: 7584165

Group type: EXPERIMENTAL
Intervention: Iron and vitamin A supplementation
Number of subjects: 74

Group type: COMPARATOR
Intervention: Healthy children (no intervention)
Number of subjects: 74
Study: 1439090

Group type: EXPERIMENTAL
Intervention: Formoterol aerosol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2883214

Group type: EXPERIMENTAL
Intervention: 25 mg alpidem
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 50 mg alpidem
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 100 mg alpidem
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 2.5 mg lorazepam
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29963684

Group type: EXPERIMENTAL
Intervention: Topical aminolaevulinic acid-photodynamic therapy with red light
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical aminolaevulinic acid-photodynamic therapy with green light
Number of subjects: 0
Study: 27346343

Group type: EXPERIMENTAL
Intervention: Moderate protein-restricted (PR) diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diet specifically reduced in branched-chain amino acids (BCAAs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: PR diet
Number of subjects: 0
Study: 26466857

Group type: EXPERIMENTAL
Intervention: Galectin-3
Number of subjects: 592

Group type: COMPARATOR
Intervention: Clinical risk model without NT-proBNP
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: NT-proBNP and cTnI
Number of subjects: 592
Study: 23387383

Group type: EXPERIMENTAL
Intervention: Self-regulation protocol (4-week duration)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Self-regulation guidebook only (comparison group)
Number of subjects: 64
Study: 21684602

Group type: EXPERIMENTAL
Intervention: Increasing age
Number of subjects: 4425

Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 4425

Group type: EXPERIMENTAL
Intervention: Nonwhite ethnicity
Number of subjects: 4425

Group type: EXPERIMENTAL
Intervention: Hyperopia
Number of subjects: 4425

Group type: EXPERIMENTAL
Intervention: Centrum (Wyeth Consumer Healthcare, Madison, NJ) use
Number of subjects: 4425

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 4425

Group type: EXPERIMENTAL
Intervention: Higher educational level
Number of subjects: 4425

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 4425

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy in female participants
Number of subjects: 4425
Study: 18955427

Group type: EXPERIMENTAL
Intervention: Traditional group (n = 20) - active assisted range of motion exercises on the day of surgery, dynamic exercises for the rotator cuff after six weeks, strengthening exercises after eight weeks.
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Progressive group (n = 14) - active assisted range of motion and dynamic exercises for the rotator cuff on the day of surgery, strengthening exercises started after six weeks.
Number of subjects: 34

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 34
Study: 17151314

Group type: EXPERIMENTAL
Intervention: Combined exercise and psychological adherence intervention (EP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Exercise-only intervention (EO)
Number of subjects: 40
Study: 12666466

Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact (kangaroo care)
Number of subjects: 146
Study: 10704545

Group type: EXPERIMENTAL
Intervention: Short-wavelength automated perimetry
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard visual fields
Number of subjects: 25
Study: 11825403

Group type: EXPERIMENTAL
Intervention: Subtotal splenectomy with retroperitoneal transposition
Number of subjects: 72

Group type: COMPARATOR
Intervention: Devascularization
Number of subjects: 72
Study: 8172793

Group type: EXPERIMENTAL
Intervention: CHOEP (4 cycles of cyclophosphamide, doxorubicin, vincristine, etoposide, prednisolone)
Number of subjects: 175

Group type: COMPARATOR
Intervention: hCHOP/IVEP (4 cycles of dose-intensified CHOP alternating with ifosfamide, etoposide, vindesine, prednisolone)
Number of subjects: 175
Study: 2963523

Group type: EXPERIMENTAL
Intervention: Celiprolol, 400 mg once daily
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 29521662

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin bolus dose of 340 IU/kg of ideal body weight (IBW)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Unfractionated heparin bolus dose of 300 IU/kg of total body weight (TBW)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: IBW group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 26439473

Group type: EXPERIMENTAL
Intervention: Metacognitive Therapy (MCT)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Behavioural Activation (BA)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Wait-list Control
Number of subjects: 46
Study: 24564933

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)-based tight control strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 mg/d prednisone added to MTX-based tight control strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo added to MTX-based tight control strategy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tight control strategies (both MTX and prednisone)
Number of subjects: 0
Study: 22616908

Group type: EXPERIMENTAL
Intervention: Sitafloxacin (STFX) 100 mg/day for 5 days
Number of subjects: 44

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) under local anaesthesia
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Sitafloxacin (STFX)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP)
Number of subjects: 44
Study: 20298418

Group type: EXPERIMENTAL
Intervention: Fluticasone (250 microg twice daily)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70